News Headlines Article

Genetic testing evolves, along with health and ethics debates
Los Angeles Times

When last we visited with the genetic testing firm 23andMe, it was in big trouble.

That was in December 2013. The Food and Drug Administration had just ruled that the company had been breaking the law in marketing its Personal Genome Service. For $99, customers spit into a tube, mailed it to 23andMe and got back a report on their carrier status or susceptibility to breast cancer, heart disease and some 250 other diseases or conditions, based on genetic information extracted from their saliva.

Commands